- Home
- ANTX vs ZYXI Comparison
ANTX vs ZYXI Comparison
Compare ANTX & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | ZYXI |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 35.8M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANTX | ZYXI |
|---|---|---|
| Price | $1.10 | $0.13 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $3.00 |
| AVG Volume (30 Days) | 61.1K | ★ 10.5M |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $108,202,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.01 | $0.12 |
| 52 Week High | $1.55 | $8.45 |
Technical Indicators
Market Signals| Indicator | ANTX | ZYXI |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 30.05 |
| Support Level | $1.03 | $0.23 |
| Resistance Level | $1.23 | $0.35 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 55.00 | 0.99 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.